NasdaqGS:LENZPharmaceuticals
A Look At LENZ Therapeutics (LENZ) Valuation After New Middle East VIZZ Distribution Agreement
LENZ Therapeutics (LENZ) shares are in focus after the company signed an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO to register and commercialize its VIZZ eye drop for presbyopia across multiple Middle Eastern markets.
See our latest analysis for LENZ Therapeutics.
The distribution deal comes after a weak run for the stock, with a 30 day share price return of 40.62% and a 90 day share price return of 61.67%, while the 1 year total shareholder return sits at...